Literature DB >> 11962732

Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells.

Noëlla Germain1, Elisabeth Boichot, Charles Advenier, Evgueni V Berdyshev, Vincent Lagente.   

Abstract

Cannabinoids are known to downregulate immune response but the role for cannabinoid receptors in cannabinoid-induced immunosuppression is still unclear. To address this question, the interference of CB1 and CB2 receptor antagonists with the inhibition of TNF-alpha production by synthetic cannabinoid WIN 55,212-2 was studied using human peripheral blood mononuclear cells (PBMC) in vitro. CB2 (SR 144528) but not CB1 (SR 141716A) receptor antagonist dose dependently interfered with WIN 55,212-2-induced inhibition of TNF-alpha synthesis. Also, WIN 55,212-2 decreased fMLP-induced reactive oxygen species generation in lipopolysaccharide (LPS)-primed PBMC. However, the high concentrations of cannabinoid receptor ligands needed to achieve significant effects suggest that the observed effects may be in part cannabinoid receptor independent.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11962732     DOI： 10.1016/s1567-5769(01)00200-4

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN： 1567-5769            Impact factor:   4.932


  8 in total

1.  The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.

Authors:  Alexandre A Steiner; Alla Y Molchanova; M Devrim Dogan; Shreya Patel; Erika Pétervári; Márta Balaskó; Samuel P Wanner; Justin Eales; Daniela L Oliveira; Narender R Gavva; M Camila Almeida; Miklós Székely; Andrej A Romanovsky
Journal:  J Physiol       Date:  2011-03-14       Impact factor: 5.182

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α.

Authors:  Eric J Downer; Eileen Clifford; Sylvie Amu; Padraic G Fallon; Paul N Moynagh
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

4.  Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis.

Authors:  Eric J Downer; Eileen Clifford; Bruno Gran; Hendrik J Nel; Padraic G Fallon; Paul N Moynagh
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

Review 5.  The endocannabinoid system in normal and pathological brain ageing.

Authors:  Andras Bilkei-Gorzo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

6.  The immunosuppressive effect of the endocannabinoid system on the inflammatory phenotypes of macrophages and mesenchymal stromal cells: a comparative study.

Authors:  Tim Ruhl; Corina Corsten; Justus P Beier; Bong-Sung Kim
Journal:  Pharmacol Rep       Date:  2020-10-07       Impact factor: 3.024

Review 7.  In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.

Authors:  Georgia Watt; Tim Karl
Journal:  Front Pharmacol       Date:  2017-02-03       Impact factor: 5.810

8.  Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.

Authors:  Antje Scholl; Igor Ivanov; Burkhard Hinz
Journal:  Oncotarget       Date:  2016-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.